Literature DB >> 27181047

Prevalence of neoplasms in definite and probable mitochondrial disorders.

Josef Finsterer1, Marlies Frank2.   

Abstract

There are some indications that the prevalence of benign and malign neoplasms is increased in patients with a mitochondrial disorder (MID). This study aimed at calculating the prevalence of malign and benign neoplasms in MID patients compared to the general population. Among 103 adult patients with definite or probable MID 16 had a malignancy (15.5%) and 11 (10.7%) a benign neoplasm. Four patients had thyroid cancer, three patients had prostate cancer, two patients each colon cancer, or ovarian cancer, and one each lung cancer, basalioma, Paget carcinoma of the skin, Bowen disease, renal cancer, and urinary bladder cancer. One patient had two carcinomas. Five patients had lipomas, two thyroid adenoma, and one each meningeoma, ovarian adenoma, hemangioma of the liver, and pituitary adenoma. Compared to the general population, the prevalence of malignancies was 3-4 fold increased in definite and probable MIDs. Compared to a cohort of myotonic dystrophy type-1 patients, the prevalence was 1.4 fold increased. In conclusion, adult MID patients seem to carry an increased risk to develop malignancy or a benign neoplasm. Females with a MID seem to be predominantly at risk to develop a neoplasm.
Copyright © 2016 Elsevier B.V. and Mitochondria Research Society. All rights reserved.

Entities:  

Keywords:  Malignancy; Mitochondrial disorder; Neoplasm; Oncogenesis; Oxidative stress; Tumour; mtDNA

Mesh:

Year:  2016        PMID: 27181047     DOI: 10.1016/j.mito.2016.05.002

Source DB:  PubMed          Journal:  Mitochondrion        ISSN: 1567-7249            Impact factor:   4.160


  10 in total

1.  The Spectrum of Renal Abnormalities in Mitochondrial Disorders Is Broad.

Authors:  Josef Finsterer
Journal:  Kidney Int Rep       Date:  2022-05-19

Review 2.  Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias.

Authors:  Teodoro Jerves; Nenad Blau; Carlos R Ferreira
Journal:  Mol Genet Metab       Date:  2022-03-28       Impact factor: 4.204

3.  Renal manifestations of primary mitochondrial disorders.

Authors:  Josef Finsterer; Fulvio Alexandre Scorza
Journal:  Biomed Rep       Date:  2017-04-12

4.  Does growth-hormone treatment affect patients with and without a mitochondrial disorder differentially?

Authors:  Josef Finsterer
Journal:  Clin Pediatr Endocrinol       Date:  2018-04-13

Review 5.  The Oncojanus Paradigm of Respiratory Complex I.

Authors:  Giulia Leone; Houda Abla; Giuseppe Gasparre; Anna Maria Porcelli; Luisa Iommarini
Journal:  Genes (Basel)       Date:  2018-05-07       Impact factor: 4.096

6.  Letter to the Editor: Endocrine Compromise in Mitochondrial Disorders.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  J Endocr Soc       Date:  2018-05-14

Review 7.  Mitochondrial Regulation of Diabetic Kidney Disease.

Authors:  Daniel L Galvan; Koki Mise; Farhad R Danesh
Journal:  Front Med (Lausanne)       Date:  2021-09-27

Review 8.  Recent advances in mitochondrial diseases: From molecular insights to therapeutic perspectives.

Authors:  Ahmad M Aldossary; Essam A Tawfik; Mohammed N Alomary; Samar A Alsudir; Ahmed J Alfahad; Abdullah A Alshehri; Fahad A Almughem; Rean Y Mohammed; Mai M Alzaydi
Journal:  Saudi Pharm J       Date:  2022-05-28       Impact factor: 4.562

9.  Robotic radical prostatectomy in a patient with prostate cancer and MERRF syndrome, a rare mitochondrial disorder affecting muscle fibers.

Authors:  Ramphis A Morales-López; Ricardo Sánchez-Ortiz
Journal:  Urol Case Rep       Date:  2018-10-05

10.  Exome sequencing and metabolomic analysis of a chronic kidney disease and hearing loss patient family revealed RMND1 mutation induced sphingolipid metabolism defects.

Authors:  Nagwa E A Gaboon; Babajan Banaganapalli; Khalidah Nasser; Mohammed Razeeth; Mosab S Alsaedi; Omran M Rashidi; Lereen S Abdelwehab; Turki Saad Alahmadi; Osama Y Safdar; Jilani Shaik; Hani M Z Choudhry; Huda Husain Al-Numan; Mohammad Imran Khan; Jumana Y Al-Aama; Ramu Elango; Noor A Shaik
Journal:  Saudi J Biol Sci       Date:  2019-10-18       Impact factor: 4.219

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.